Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ADC Therapeutics ( (ADCT) ) has issued an announcement.
On October 12, 2025, ADC Therapeutics announced a $60 million private placement with institutional investors, expected to close on October 27, 2025. The proceeds will support the commercial expansion of ZYNLONTA and strengthen the company’s balance sheet, positioning it for long-term growth and a potential relaunch of ZYNLONTA in 2027.
The most recent analyst rating on (ADCT) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on ADC Therapeutics stock, see the ADCT Stock Forecast page.
Spark’s Take on ADCT Stock
According to Spark, TipRanks’ AI Analyst, ADCT is a Neutral.
ADC Therapeutics’ stock score is primarily impacted by its financial instability and ongoing losses, despite strong technical momentum. The negative P/E ratio and lack of dividend yield further weigh on the valuation. While the earnings call provided some positive future growth potential, the restructuring costs and increased net losses are concerning.
To see Spark’s full report on ADCT stock, click here.
More about ADC Therapeutics
ADC Therapeutics is a commercial-stage global leader in the field of antibody drug conjugates (ADCs), focusing on treating hematologic malignancies and solid tumors. The company is advancing its proprietary ADC technology, with its CD19-directed ADC ZYNLONTA receiving accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma.
Average Trading Volume: 827,696
Technical Sentiment Signal: Buy
Current Market Cap: $497.2M
For detailed information about ADCT stock, go to TipRanks’ Stock Analysis page.